Citation

James A. Adv. Psychiatr. Treat. 2008; 14(1): 10-16.

Copyright

(Copyright © 2008, Royal College of Psychiatrists)

DOI

10.1192/apt.bp.107.003830

PMID

unavailable

Abstract

Recent controversy over the use of serotonin reuptake inhibitors in children and adolescents has focused attention on the role of the pharmaceutical industry in the treatment of young people. Failure of pharmaceutical companies to fully disclose negative outcome trials has led to new guidelines for publication of all trial results. Scrutiny is on the conduct of trials and the relationship of the pharmaceutical industry with prescribing doctors and posttrial surveillance of new drugs. It is argued that drug treatments in child psychiatry are a powerful therapeutic tool but vigilance is needed to ensure that data on the efficacy and safety of drugs are freely available.

Language: en

Keywords

human; suicide; child; autism; suicidal ideation; depression; psychosis; clinical trial; article; bulimia; eating disorder; mental disease; prescription; antidepressant agent; neuroleptic agent; child psychiatry; community care; fluoxetine; paroxetine; serotonin uptake inhibitor; cognitive therapy; anxiety disorder; practice guideline; publication; drug safety; placebo; drug industry; follow up; psychosocial care; drug efficacy; risperidone; drug tolerability; pharmaceutical care; drug research; attention deficit disorder; risk reduction; Gilles de la Tourette syndrome; low drug dose; drug contraindication; obsessive compulsive disorder; drug formulation; treatment response; unspecified side effect; off label drug use